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thereby providing additional information on secondary care in England. This 
study aimed to generate more accurate resource use for the management of CLL 
and iNHL by using the THIN-HES database. Methods: First, a MEDLINE and UK 
Health Technology Appraisals (HTAs) reviews were undertaken to identify stud-
ies documenting the cost of previously-treated iNHL and CLL in the UK. Then, to 
collect patients health care resource use, THIN database linked to the HES dataset 
was analysed. Results: Three HTAs were identified as relevant, and cost esti-
mates relied on assumptions from clinical experts. Assumptions varied as TA193 
related to relapsed CLL assumed that health care visits were three times more 
frequent post-progression (3 consultations/month: £86) than pre-progression (1 
consultation/month: £28.67) while another, TA202, assumed a rather constant 
number of visits across the two health states (1 clinic visit per month: £121.11). 
Therefore, analyses of the THIN database linked to HES were undertaken, includ-
ing more than 1 000 patients. OPCS4 codes and READ codes in the HES and THIN 
databases respectively, were used to identify treatments prescribed and proce-
dures undertaken. Costs were estimated by applying unit costs from national 
references. ConClusions: To our knowledge, this analysis is the first retrospec-
tive observational study to assess the cost of managing previously-treated CLL 
and iNHL in the UK. This study will serve as an important resource in the health 
economic evaluation of emerging therapies. This method suggests a greater stand-
ardization of disease management costs across HTAs.
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objeCtives: Despite the fact that short and long-term effects of the exposure to 
air pollution on health have been extensively analyzed, estimates of the health 
care economic impact of such effects are still limited. We therefore carried out a 
systematic review of the literature, with the aim of identifying the current major 
research focuses in the field and the topics that will need to be addressed in the 
future. Methods: We searched the electronic databases MEDLINE and EMBASE, 
in which we applied respectively the following algorithms: 1) “((“cost of illness” 
[MeSH Terms] OR “health care costs” [MeSH Terms] OR “health expenditures” [MeSH 
Terms]) AND “environmental pollution” [MeSH Terms]) OR (Pollution [Title/Abstract] 
AND (Expenditure [Title/Abstract] OR Expenditures [Title/Abstract] OR cost [Title/
Abstract] OR costs [Title/Abstract]) AND (health [Title/Abstract] OR health care [Title/
Abstract]))“; 2) “‘health care cost’/exp AND ‘pollution’/exp”. Searches were limited 
to article written in English and Italian, without any date restriction. Results: 
The initial selections identified 775 records in MEDLINE and 466 in EMBASE, 149 
of which were classified as relevant. They focused on a wide range of pollutants, 
including volatile organic compounds, nitrogen dioxide, pesticides, ozone, particu-
late matter and tobacco smoke. Most of the studies assessed the health impact of 
environmental pollutants using direct and indirect cost estimates acquired from 
literature, mainly relying on cost of illness methods; 27 papers used an individual 
direct health care costs approach, but they usually didn’t involve indirect costs in 
the final computations. Finally, only a few studies distinguished between short-term 
and long-term effect of air pollution. ConClusions: The results of our review iden-
tified two main topics that deserve further research: future health impact assess-
ments should integrate indirect costs estimates with information from the direct 
modeling of real-life health care costs; the short- and long-term economic impacts 
should be clearly separated.
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objeCtives: This analysis assessed the cost effectiveness of ipilimumab 3mg/
kg as first-line treatment for metastatic melanoma. As ipilimumab has an exist-
ing second-line recommendation, the decision problem is ipilimumab first-line 
followed by best supportive care (BSC), compared with Scottish clinical practice 
- dacarbazine or vemurafenib first-line followed by ipilimumab. Methods: In line 
with SMC requirements, an area under the curve model was built comparing first-
line ipilimumab, dacarbazine and vemurafenib. The model utilised progression, 
survival and utility data from CA184-024 for ipilimumab/dacarbazine and dacar-
bazine, survival data from MDX010-20 for ipilimumab second-line, and survival 
and progression data from BRIM-3 for vemurafenib. MDX010-20 and observational 
data, using the approved regimen, were tested within scenario analyses assessing 
the performance of ipilimumab 3mg/kg at first-line. 2013 costs were taken from 
Scottish or UK official sources. Results: Economic analysis, including patient 
access schemes for ipilimumab and vemurafenib, shows that ipilimumab first-
line followed by BSC is cost-effective versus dacarbazine first-line followed by 
ipilimumab (incremental costs: £10,502, incremental quality-adjusted life-years 
[QALYs]: 0.33, incremental cost-effectiveness ratio [ICER]: £31,481). Compared with 
ipilimumab first-line followed by BSC, the sequence vemurafenib first-line fol-
lowed by ipilimumab is associated with incremental QALYs (0.26) but also incre-
mental costs (£33,306), resulting in a not cost-effective cost/QALY trade-off (ICER 
= £126,482), i.e. ipilimumab first-line should be the preferred option. A scenario 
analysis that compared ipilimumab first-line with vemurafenib first-line alone 
resulted in ipilimumab being the dominant treatment option. Comprehensive 
sensitivity analyses identified survival parameters as having the largest impact 
on model results. Ipilimumab remained cost-effective at a threshold of £50,000 
per QALY gained against both comparators. ConClusions: First-line ipilimumab 
treatment for melanoma is cost-effective, and as a first-line option it would 
expand clinician choice, enabling selection of the most appropriate therapy for 
patients depending on their disease characteristics and BRAF mutation status.
Mauskopf et al. in 2005 and 2007. ConClusions: Based on the results we suggest the 
following definition for BIA: “A budget impact analysis is a form of health economic 
evaluation. Its purpose is to predict the financial consequences of the introduction 
or removal of an intervention from the current health care setting. Therefore BIA 
is a framework to synthesize the best available evidence. Rather than calculating 
a precise impact number it provides a valid model to the decision maker, enabling 
him to understand the relative effects of his decisions. The analysis is undertaken by 
modeling two scenarios where the reference scenario is the status quo and the second 
scenario a simulation of the decision to be made. The model parameters are chosen 
according to the framework requirement of the decision maker.”
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objeCtives: To explore patient characteristics, resource use and costs related to 
different episodes of care (EOC) in Finnish health care. EOC is a health problem 
needing testing, diagnosis, care or follow-up from its first presentation by the 
patient to health care until the completion of the last health care contact for 
it. Literature around costs of episodes (COE) is scarce. Methods: Primary and 
secondary care data was collected during the three months prospective, non-
randomized follow-up study (Effective Health Centre) using questionnaires and 
electronic health record. Setting included three primary health care practices in 
Pirkanmaa, Finland. 622 (41% of potential) patients were recruited during one 
week period. Patients that had doctor/nurse appointment on the recruiting day 
and agreed to participate were included. Patients visiting specialized health guid-
ance clinic for pregnant women, children and mothers were excluded. The main 
outcome measures were patient characteristics, resource use and costs classified 
based on the International Classification of Primary Care (ICPC-2) episode title 
codes. Resource use was valued with health care providers’ 2012 unit costs. Social 
Insurance Institution costs (e.g. outpatient drugs) were excluded. Results: On 
average, patient had 1.22 EOCs during the three months. Patient characteristics 
and resource use differed between the EOC-classes. Class L ‘Musculoskeletal’ had 
the highest number of episodes (17%). The most common (8%) single EOC was 
‘upper respiratory infection’. The mean COE was € 390 (SE € 61) and the median COE 
was € 165 (IQR € 118-289) during the three month follow-up. The most expensive 
class was K ‘Circulatory’, with a mean COE of € 910. The most expensive single COE 
(€ 32,546) was in the group K. The most expensive one percent of COEs summed up 
covered 36% of total COEs. ConClusions: Patient characteristics, resource use 
and costs differed between the ICPC-2 classes, which could be taken into account 
in evaluations, planning and pricing.
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objeCtives: In the last twenty years there has been an intense debate on how to 
value lost productivity in economic evaluations. According to the Washington panel, 
lost productivity influences health-related quality of life (HRQoL) and should thus 
be considered a health effect instead of a cost to avoid double counting. Until now 
empirical evidence on the inclusion of income loss when valuing health states is 
not decisive. We examine the relationship between three aspects of lost productiv-
ity (work-status, absenteeism and presenteeism) and patient or social valuation of 
health-related quality of life. Methods: Cross-sectional survey data from a total of 
830 respondents with a rheumatic disorder from four Western-European countries. 
Health-related quality of life was expressed in either the European societal utility 
using EQ-5D-3L or the patient valuation using EQ-VAS. Linear regression analyses 
were performed to examine the impact of work-status (four categories), absen-
teeism (absent from paid work during the past three months), and presenteeism 
(QQ method) on EQ-5D utilities and VAS scores taking demographic characteris-
tics and disease severity (duration, pain and restriction) into account. Results: 
The relationship between work-status, absenteeism or presenteeism and HRQoL 
is stronger for patient valuation than societal valuation. Compared to work-status 
and presenteeism is the relationship between absenteeism and HRQoL even less 
explicit. However, results for all measures of work are only marginal significant 
and negligible compared to the influence of restriction due to disease we studied.  
ConClusions: In four European countries, analyses among patients with a rheu-
matic disorder do not fully support the claim of the Washington panel that lost 
productivity has a significant relationship with HRQoL, and this is even more appar-
ent for absenteeism than for work-status and presenteeism. Therefore absenteeism 
should continue to be included in the costs and not in the QALY. Findings need to 
be confirmed in other disease areas.
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objeCtives: Accurate cost data are required to inform cost-effectiveness assess-
ments of novel treatments in the UK for NICE appraisals. Up to now, levels of 
resource use to manage CLL and iNHL have mainly been based on clinical expert 
opinion. However, recently, two key primary care databases in the UK (THIN and 
CPRD) were linked with Hospital Episode Statistics (HES) at the patient level, 
